A than group B (thrombotic, 3.6% vs 1.5%; P ¼ .02; device related, 5% vs 0.5%; P < .0001).
Author Disclosures: R. Chaer: Nothing to disclose; E. D. Dillavou: Nothing to disclose; L. Fish: Nothing to disclose; E. Genovese: Nothing to disclose; E. Hager: Nothing to disclose; S. A. Hirsch: Provensis,Research Grants; M. Kiguchi: Nothing to disclose. Objectives: Previous studies have combined anastomotic, catheter-induced, and IFAA to achieve adequate numbers for analysis, and have recommended repair of asymptomatic IFAA with diameters $2.5 cm and all symptomatic IFAA. This study evaluates the contemporary management of IFAA, using these criteria.
S6: SVS
Methods: Patients with IFAA were evaluated using a standardized, prospectively maintained database by a research consortium.
Results: From 2002-2012 236 IFAA were identified in 182 patients (mean age, 72; M:F, 16 :1) at eight institutions. Nonoperative mean diameter was 2.8 6 .7 cm; operative diameter was 3.3 6 1.5 cm. IFAA location was: CFA (191), SFA (34), and PFA (11). Synchronous aneurysms (mean ¼ 1.7/patient) occurred in the aorta (181), iliac (126), popliteal (96), hypogastric (63), mesenteric (17) arteries, and contralateral SFA (7) and PFA (2). 66% of repaired aneurysms were asymptomatic; other indications included: claudication (18%), local pain (8%), nerve compression (3%), rupture (3%), acute thrombosis (1%), embolus (1%), and rest pain (.5%). Acute complications (rupture, thrombosis, embolus) were associated (P < .05) with FAA diameter >4 cm and intraluminal thrombus, but not location. Mean diameter of symptomatic aneurysms was: rupture, 5.7 6 1.3 cm; thrombosis, 4 6 1.1 cm; and embolus, 3.6 6 .1 cm. 174 IFAA were repaired with interposition or bypass graft; three underwent endovascular repair. There were two perioperative deaths at 30 days (MI, MSOF); operative complications included wound infection (6%), seroma (3%), and bleeding (2%). No amputations occurred up to 5 years in either the nonoperative or operative groups. Survival was: 3 months ¼ 99% (138), 1 year ¼ 92% (n ¼ 104), and 5 years ¼ 81% (20) Background: Transcatheter aortic valve replacement (TAVR) has revolutionized treatments for patients with severe symptomatic aortic valve stenosis. In 2011 FDA approved TAVR for surgically inoperable patients, and in 2012 for surgical high risk patients. Currently randomized trials are underway evaluating the efficacy of TAVR for surgical low risk patients. Similar to TEVAR, TAVR requires navigation of 22-25Fr sheaths and catheters across the aortoiliac segments and expose patients to the risks of arterial injury, bleeding, and stroke. As vascular surgeons we have participated in nearly 100 TAVR procedures, and can attest to the importance of vascular surgeons involvement in not only limiting patient risks, but also in expanding the indications for patients with critical aortic stenosis and no other treatment options, as well as in managing bailouts following complications of these procedures.
Technical Description: This video presentation will focus on the implications of appropriate access during TAVR. Tips and tricks to the bailout procedures needed during misplaced aortic valves that require retrieval, as well as diagnosis and treatments for arterial injury during trans-femoral and trans-apical TAVR. Objectives: Acute limb ischemia (ALI) in pediatric patients is rare but may lead to limb loss and life-long complications. The aim of this study was to review the experience of a Canadian tertiary pediatric center with the medical and operative management of ALI.
Methods: The charts of in-patients diagnosed with acute upper or lower limb ischemia between 1999-2012 were reviewed. Patient demographics, arterial clot site and etiology, intervention, anticoagulation type and duration, and short and long-term complications were analyzed.
Results: 136 patients presented with signs of limb ischemia (46% female, 34% younger than 30 days, 51% between 1-12 months, and 15% between 1-18 years). 95% involved the lower limbs. 85% of arterial clots were totally occlusive. 92% were due to vessel catheterization, 5% were idiopathic, and 2% were due to hereditary hypercoagulable states. 96% were managed nonoperatively. Patients were treated with a combination of thrombolysis, unfractionated or low molecular-weight heparin, aspirin and/or warfarin (duration, 1 day-13 years). All patients were followed postdischarge at our institution or at their referring hospital (average, 3.5 years). 13% had complications related to ALI or anticoagulation (limb length or thigh circumference discrepancy, or intracranial hemorrhage). 25 patients died of unrelated causes (sepsis, multi-organ dysfunction, or cardiac failure).
Conclusions: In contrast with adults, ALI in children can generally be managed nonoperatively with anticoagulation, likely because of their greater ability to develop arterial collaterals. Long-term follow-up by a multidisciplinary team of pediatric and surgical specialists and allied health professionals is integral to achieving a successful outcome.
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